Literature DB >> 2833302

Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma.

A Zaniboni1, E Simoncini, P Marpicati, G Marini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2833302      PMCID： PMC2246531          DOI： 10.1038/bjc.1988.71

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  6 in total

1.  Two-stage plans for patient accrual in phase II cancer clinical trials.

Authors:  Y J Lee; M Staquet; R Simon; R Catane; F Muggia
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

2.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

3.  Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.

Authors:  D Machover; E Goldschmidt; P Chollet; G Metzger; J Zittoun; J Marquet; J M Vandenbulcke; J L Misset; L Schwarzenberg; J B Fourtillan
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

4.  Selective modulation of 5-fluorouracil action in patients with colorectal carcinoma.

Authors:  Y M Rustum
Journal:  Chemioterapia       Date:  1985-10

5.  Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients.

Authors:  E Sciarrino; R G Simonetti; S Le Moli; L Pagliaro
Journal:  Cancer       Date:  1985-12-15       Impact factor: 6.860

Review 6.  Primary hepatocellular cancer--present results and future prospects.

Authors:  M A Friedman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-12       Impact factor: 7.038
  6 in total
  4 in total

1.  In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Hepatocellular carcinoma.

Authors:  S Badvie
Journal:  Postgrad Med J       Date:  2000-01       Impact factor: 2.401

3.  Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Junichi Shindoh; Yehuda Z Patt; Robert E Roses; Giuseppe Zimmitti; Richard D Lozano; Manal M Hassan; Hesham M Hassabo; Steven A Curley; Thomas A Aloia; James L Abbruzzese; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2013-07-02       Impact factor: 6.860

4.  Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma.

Authors:  Koji Uchino; Shuntaro Obi; Ryosuke Tateishi; Shinpei Sato; Miho Kanda; Takahisa Sato; Toru Arano; Kenichiro Enooku; Eriko Goto; Ryota Masuzaki; Hayato Nakagawa; Yoshinari Asaoka; Yuji Kondo; Noriyo Yamashiki; Tadashi Goto; Shuichiro Shiina; Masao Omata; Haruhiko Yoshida; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2012-03-22       Impact factor: 6.772
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.